Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

ELI Lilly & Q3 2026 Results: Net Income $6.45B, Up 15.5% YoY

Eli Lilly reported significant growth for the third quarter of 2026, with revenue increasing to $24.40 billion from $17.60 billion in the prior year. Net income for the nine months ended September 30, 2026, rose to $20.94 billion, driven by strong operational performance despite a substantial $7.54 billion charge for acquired in-process research and development.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue24,397.017,601.0
Profit before tax8,406.07,233.0
Net income6,451.05,583.0
EPS (diluted, $ a share)$7.22$6.21

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+15.5%
Revenue, year on year+38.6%
Source

10-Q filed with the SEC, NYSE: LLY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

ELI Lilly & Co: key numbers

Share price
$1,431.67Close, Nov 16
Market cap
$1.35T
Shares outstanding
940.75MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from ELI Lilly & Co

All →
4:15 PM ET Form 4
Insider Selling

ELI Lilly & EVP, GC & Secretary Anat Hakim Sells $7.01M of Stock

Anat Hakim, EVP, GC & Secretary, sold 5,000 shares of ELI Lilly & Co at $1,402.52 a share, worth $7.01M in total on Nov 2, 2026. Shares held after the trade: 4,137 (-54.7%).

Value
$7.01M
Shares
5,000
Price
$1,402.52
Role
EVP, GC & Secretary
Holding change
-54.7%
Trade date
Nov 2, 2026
7:04 AM ET 8-K
Financial Results

ELI Lilly & Financial Results

Eli Lilly reported Q3 2026 revenue of $24.4 billion, a 39% increase driven by strong demand for Mounjaro and Zepbound. The company raised its full-year 2026 revenue guidance midpoint by $5.5 billion to a range of $91.0 to $92.0 billion, reflecting robust global consumer demand and expanded coverage for obesity care.

Term
Q3 2026

“Lilly had another strong quarter, exceeding our prior expectations and allowing us to raise our full-year outlook. Revenue growth was driven by broad global consumer demand for Mounjaro and Zepbound, the global launches of Foundayo, expanded U.S. coverage for obesity care and a doubling in our newest products in oncology, immunology and neuroscience.”

David A. Ricks, Lilly chair and CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.